Outlier: Takeda Scores Chinese Clinical Trial Authorization For Diabetes Agent In Record 7 Months
This article was originally published in PharmAsia News
It’s not an anticancer therapy, and it has only Phase II data from overseas, but Takeda has managed to cut the average clinical trial authorization time for Class 1 new drugs in China by two months.
You may also be interested in...
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
SHANGHAI - China's State FDA issued regulations on a special approval procedure to accelerate the approval process for new drug applications, effective Jan. 7
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.